RedHill Biopharma Reports Financial Results for the First Quarter of 2013 (May 2 2013) RedHill Biopharma Reports Financial Results for the First Quarter of 2013 (May 2 2013) – Hebrew
Read More...News
RedHill Biopharma Submits NDA for U S Marketing of RHB-103 Anti-Migraine Oral Thin Film RedHill Biopharma Submits NDA for U S Marketing of RHB-103 Anti-Migraine Oral Thin Film – Hebrew
Read More...RedHill Biopharma Provides Update on RHB-101 (Cardio) Scientific Advice Meeting and Planned Marketing Application Submission in Europe RedHill Biopharma Provides Update on RHB-101 (Cardio) Scientific Advice Meeting and Planned Marketing Application Submission in Europe – Hebrew
Read More...RedHill Biopharma to Present at the 25th Annual ROTH Conference – March 19 2013
Read More...RedHill Biopharma Provides Update on Development Progress and Planned NDA Submission for RHB-102 (Feb 25 2013) – Hebrew RedHill Biopharma Provides Update on Development Progress and Planned NDA Submission for RHB-102 (Feb 25 2013)
Read More...RedHill Biopharma Reports 2012 Fourth Quarter and Year-End Results (February 19 2013)- Hebrew RedHill Biopharma Reports 2012 Fourth Quarter and Year-End Results (February 19 2013)
Read More...RedHill Announces Notice of Allowance for US patent application – RHB-101 (Cardio)
Read More...RedHill announces new patent and provides update on RHB-104 (Crohn’s) RedHill announces new patent and provides update on RHB-104 (Crohn’s) – Hebrew
Read More...RedHill to commence NASDAQ listing and trading today under the ticker “RDHL” RedHill to commence NASDAQ listing and trading today under the ticker “RDHL” (Hebrew)
Read More...RedHill Biopharma Announces Successful Completion of $6.5 Million Private Placement RedHill Biopharma Announces Successful Completion of $6.5 Million Private Placement (Hebrew)
Read More...RedHill Announces Notice of Allowance for a new U.S. patent for RHB-104 (Crohn’s) RedHill Announces Notice of Allowance for a new U.S. patent for RHB-104 (Crohn’s) – Hebrew
Read More...RedHill plans NDA filing with RHB-103 (migraine) after positive Pre-NDA meeting with FDA
Read More...RedHill to initiate PII Multiple Sclerosis study with RHB-104 following positive pre-clinical studies RedHill to initiate PII Multiple Sclerosis study with RHB-104 after positive pre-clinical results (Hebrew)
Read More...RedHill Biopharma filed a registration statement for NASDAQ listing (Sept 13 2012) RedHill Biopharma filed ADR listing documents on NASDAQ (Sept 13, 2012) – (Hebrew)
Read More...RedHill announces successful pivotal BE trial results with RHB-103 (Migraine) (May 28 2012) RedHill announces successful pivotal BE trial results with RHB-103 (Migraine) – Hebrew – (May 28 2012)
Read More...RedHill Biopharma commenced advanced clinical trial with RHB-103 (Migraine) (April 24 2012) English RedHill Biopharma commenced advanced clinical trial with RHB-103 (Migraine) (April 24 2012) Hebrew
Read More...RedHill announces successful pivotal BE trial results with RHB-102 (nausea and vomiting) – April 17, 2012 RedHill announces successful pivotal BE trial results with RHB-102 (nausea and vomiting) – Hebrew – April 17, 2012 See Dror Ben Asher (CEO) and Gilead Raday’s (VP Product Development) TV interview regarding RHB-102 trial results (Hebrew): http://www.bizportal.co.il/shukhahon/biznews02.shtml?mid=315186&strsrh=רדהיל
Read More...http://www.mfa.gov.il/MFA/InnovativeIsrael/No-more-nausea-after-chemo-1-Mar-2012
Read More...RedHill Biopharma commences advanced clinical trial with RHB-102 (Nausea and Vomiting) (February 14 2012) RedHill Biopharma commenced advanced clincial trial with RHB-102 (Nausea and Vomiting) (February 14 2012) Hebrew
Read More...RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Nausea and Vomiting) Feb 12th 2012 RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Nausea and Vomiting) Feb 12th 2012 (Hebrew)
Read More...RedHill Biopharma obtains a CTA approval to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) (February 5th 2012) RedHill Biopharma obtains a CTA approval to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) (February 5th 2012) Hebrew
Read More...See Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients): http://israel21c.org/health/daily-pill-to-vanquish-nausea-after-chemo
Read More...IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial
Read More...Please use the link below to watch Dr. Jeff Lehighton, RedHill Biopharma’s Chairman of the Advisory Board, on Bloomberg TV: http://www.bloomberg.com/video/80653140/
Read More...RedHill engages with CRO for potential pivotal trial with RHB-102 (Prevention of Nausea Vomiting ) (Hebrew) RedHill engages with CRO in preparation for potential pivotal trial with RHB-102 (prevention of nausea & vomiting )
Read More...RedHill appoints Prof O’Morain as Lead Investigator for the European Phase III clinical trial with RHB-104 (Crohn’s) Hebrew Redhill appoints Prof O’Morain as Lead Investigator for the European Phase III trial with RHB-104 – Crohn’s (October 24 2011)
Read More...RedHill Biopharma appoints Prof Graham as Lead Investigator for RHB-104 – Crohn’s (Hebrew) (October 5, 2011) RedHill Biopharma appoints Prof Graham as Lead Investigator for the US pivotal trial with RHB-104 – Crohn’s (October 5, 2011)
Read More...RedHill acquires exclusive rights to a diagnostic test for RHB-104 – Crohn’s (Sep. 19 2011)
Read More...IntelGenx Announces Licensing of Anti-Psychotic VersaFilm Product
Read More...RedHill Biopharma Appoints Advisory Board (Hebrew) (April 3rd 2011) RedHill Biopharma Appoints Advisory Board (English) (April 3rd 2011)
Read More...RedHill appoints Teva’s former CFO, Dan Seusskind, as Director (English) (Feb. 22, 2011) RedHill appoints Teva’s former CFO, Dan Seusskind, as Director (Hebrew) (Feb. 22, 2011)
Read More...RedHill Biopharma Announces Successful IPO (English)(Feb. 7, 2011) RedHill Biopharma Announces Successful IPO (Hebrew)(Feb. 4, 2011)
Read More...Share and Warrant Ticker and ISIN Details
Read More...Completion of Financing (Nov. 5, 2010) (IN ENGLISH) Completion of Financing (Nov. 3, 2010) (IN HEBREW)
Read More...VersaFilm-Poster CPhI Oct. 2010 Paris
Read More...RedHill Biopharma Raises $3.5M in a Private Placement The Company Reports the Closing of Two Transactions and the Possibility of an IPO Tel Aviv, September 12, 2010 – RedHill Biopharma Ltd, an Israeli biopharmaceutical company, has completed the first part of a private placement, raising $3.5 million dollars. The Company also reports the final closing [...]
Read More...GIACONDA COMPLETES SALE OF MYOCONDA, HELICONDA AND PICOCONDA Sale of patents brings significant cash injection into Giaconda Giaconda stands to benefit if the patents are successfully commercialised Sydney, NSW, 31 August 2010 – Giaconda Limited (ASX:GIA) (the “Company”) today announced that it has completed the sale of its Myoconda, Heliconda and Picoconda patents to RedHill [...]
Read More...IntelGenx and RedHill Announce Definitive Agreement for Anti-Migraine Film Product SAINT LAURENT, QUEBEC–(Marketwire – Aug. 30, 2010) – IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) (“IntelGenx”) and RedHill Biopharma Ltd., an Israeli corporation (“RedHill”) today announced that they have entered into a co-development and commercialization agreement for IntelGenx’ first oral thin film product based upon the IntelGenx’ proprietary [...]
Read More...BOTHELL, WA, May 6, 2010, – SCOLR Pharma, Inc. (NYSE AMEX: DDD) today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation [...]
Read More...Egalet and RedHill Biopharma enter into an exclusive license agreement to develop, and commercialize Egalet’s EG-P042 (Carvedilol) for the treatment of certain cardiac diseases [...]
Read More...